Skip to main content

NEUROCRINE BIOSCIENCES INC

For the period ended Mar 31, 2025. Filed May 5, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 5, 2025

NBIX$168.86+2.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Balance Sheets

(in millions, except per share data)March 31,2025December 31,2024
Assets
Current assets:
Cash and cash equivalents$194.1$233.0
Available-for-sale debt securities749.4843.1
Accounts receivable516.0479.1
Inventory59.157.4
Other current assets119.3112.1
Total current assets1,637.91,724.7
Deferred tax assets499.4485.7
Available-for-sale debt securities815.3739.5
Right-of-use assets502.2509.4
Equity investments94.2124.8
Property and equipment, net87.082.6
Intangible assets, net36.436.5
Other noncurrent assets15.315.5
Total assets$3,687.7$3,718.7
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable and accrued liabilities$475.2$461.6
Other current liabilities47.746.1
Total current liabilities522.9507.7
Noncurrent operating lease liabilities447.5455.1
Other noncurrent liabilities181.6166.2
Total liabilities1,152.01,129.0
Stockholders’ equity:
Preferred stock, $0.001 par value; 5.0 shares authorized; no shares issued and outstanding——
Common stock, $0.001 par value; 220.0 shares authorized; 99.0 and 99.4 shares issued and outstanding, respectively0.10.1
Additional paid-in capital2,531.92,554.6
Accumulated other comprehensive income9.05.8
(Accumulated deficit) Retained earnings(5.3)29.2
Total stockholders’ equity2,535.72,589.7
Total liabilities and stockholders’ equity$3,687.7$3,718.7
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.